Tag:
ADHD
Latest Headlines
Latest Headlines
Supernus plots product launches as it dusts off $76M IPO attempt
Supernus Pharmaceuticals has finally dusted off the paperwork and suggested a $12 to $14 price range on some 5.8 million shares.
Shire pits Vyvanse against Concerta in ADHD trials
Shire is taking aim at Johnson & Johnson's ( $JNJ ) Concerta . The Irish drugmaker is sponsoring two head-to-head trials pitting its ADHD drug Vyvanse against the J&J product as a treatment for adolescents with the disorder.
ADHD community seeks DEA action in med shortages
"When you have a controlled substance problem, the DEA has to be involved in fixing it," says Ruth Hughes, CEO at Children and Adults with Attention Deficit/Hyperactivity Disorder. Drugs like
DEA quotas allow ADHD generics to run short
In yet another object lesson about the complexities of drug shortages, The New York Times takes a look at scarce ADHD medications. Anyone who's been following the ongoing drug-shortage mess knows
Shire eyes EU for Vyvanse launch
Shire is hoping to overcome European skepticism about amphetamine-based stimulants for ADHD and snag an approval for Vyvanse by the end of the year. As Reuters notes, there are no amphetamine-based
FDA-backed study finds scant evidence of heart problems from ADHD meds
ADHD drugs have been further cleared of blame for heart risks in people who take the widely used meds. In the largest study of its kind ever, researchers found that there was "little evidence" that
Researchers move closer to ADHD imaging biomarker
ADHD (attention deficit hyperactivity disorder): Hmm... that's controversial. To some people it's a complex developmental and psychiatric disorder, and to others it's code for badly behaved children
Antipsychotics, ADHD meds fuel rising psych-drug use
With sales figures showing that individual psych meds are among Big Pharma's best sellers--think Eli Lilly's ( $LLY ) Zyprexa , for one--it's no surprise to see the percentage of Americans using drugs
NEJM study finds no CV risks for ADHD drugs
Some of the cloud hanging over attention deficit hyperactivity disorder drugs has evaporated. A new study published in The New England Journal of Medicine found ADHD drugs didn't increase the risk of
Brain Resource scores $10M, opens SF office
Brain Resource ($BRRZY), an Australian provider of web-based products for brain research, has landed in San Francisco with $10 million to ramp up its presence in the research, patient care and...
